New Strategies for Combined Radioiodine Therapy in Refractory Thyroid Cancer.
- Author:
So Won OH
1
;
Jin Chul PAENG
;
June Key CHUNG
Author Information
- Publication Type:Review
- Keywords: Radioiodine; Refractory thyroid cancer; Redifferentiation therapy; Molecular targeted therapy
- MeSH: Humans; Iodine; Molecular Targeted Therapy; Prognosis; Thyroid Gland; Thyroid Neoplasms*
- From:Journal of Korean Thyroid Association 2015;8(1):26-35
- CountryRepublic of Korea
- Language:Korean
- Abstract: The prognosis of differentiated thyroid cancer (DTC) is excellent, which is mainly due to the high therapeutic efficacy of radioactive iodine (RAI) therapy as well as indolent nature of thyroid cancer itself. Although most patients with DTC are well treated with RAI therapy, a certain number of patients have been suffered from refractoriness to RAI therapy. To overcome refractoriness, many alternative treatments have been investigated, and they could be classified based on the mechanisms of action; redifferentiation drug and molecular targeted drug. Not only redifferentiated drugs but also molecular targeted drugs could induce differentiation of thyroid cancer cells. Consequently, alternative treatments allowing tumor cells of RAI avidity followed by RAI therapy could utilize a synergistic effect of both therapies. Combined RAI therapy is expected to improve therapeutic effects and prognoses of RAI refractory thyroid cancers.
